Subcutaneous delivery of immune checkpoint inhibitors: new route replacing intravenous administration?

Transl Lung Cancer Res. 2024 Apr 29;13(4):947-951. doi: 10.21037/tlcr-24-63. Epub 2024 Apr 18.

Author

Affiliation

¹ Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.

No abstract available

Keywords: IMscin001; Subcutaneous; atezolizumab; immune checkpoint inhibitor (ICI); recombinant human hyaluronidase PH20 (rHuPH20).

Publication types

Editorial
Comment